
Sep 9, 2026
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient managementDecisionDx-SCC's Class 1A (low risk) result demonstrated a 97.3% negative predictive value, supporting confidence in de-escalation decisions, while its Class 2B (highest risk) result identified patients most likely to benefit from adjuvant radiation therapyFRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Bioscie






